The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 22, 1989

Filed:

Dec. 17, 1987
Applicant:
Inventors:

Jozsef Knoll, Budapest, HU;

Sandor Harmath, Budapest, HU;

Janos Nagy, Szentendre, HU;

Berta Knoll, Budapest, HU;

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K / ; A61K / ; A61K / ;
U.S. Cl.
CPC ...
530380 ; 424 855 ; 424101 ; 514-8 ; 514 21 ; 530395 ; 530830 ;
Abstract

The selective appetite-regulating substances satietin and satietin-D had up to the present been prepared from human or animal blood serum or plasma by ultrafiltration, gel chromatography, treatment with trichloroacetic acid, affinity chromatography and optionally treatment with a proteolytic enzyme. According to the invention, satietin and satietin-D are obtained in a purified form by using immunoabsorption. Being glycoproteins, both satietin and satietin-D form antibodies (antisatietin and antisatietin-D, respectively) in the living organism and can be isolated from the blood and bound to a gel column. For the preparation of satietin and satietin-D, respectively, the human or animal blood plasma or serum is subjected to ultrafiltration and the ultrafiltrate, containing in addition to satietin and satietin-D other constituents with a molecular weight below 50000 daltons, is contacted with the gel column. The antibody bound to the gel column forms with satietin or satietin-D, respectively, an immunocomplex remaining on the column while the other constituents of the ultrafiltrate can be eluted by a buffer. Then, the immunocomplex is cleaved, whereby satietin or satietin-D, respectively, can be eluted in a purified form from the column. The column containing the antibody may repeatedly be used.


Find Patent Forward Citations

Loading…